Download curriculum vitae

CURRICULUM VITAE
DATE: July 2008
NAME:
Avi B. Markowitz, M.D.
PRESENT POSITION AND ADDRESS:
June 15, 2005 – Present Professor and Chief
Bill and Louise Bauer Distinguished Chair in Cancer Research
Area Medical Director, Hematology/Oncology Clinic
Associate Director for Clinical Research, Comprehensive Cancer Center
Director, Oncology Clinical Trials
The University of Texas Medical Branch
Department of Internal Medicine
Division of Hematology/Oncology
301 University Blvd.
Galveston, Texas 77555-0565
(409) 772-1164
EDUCATION:
July 1984-June 1986
University of California, San Francisco
San Francisco, CA Cancer Research Institute
Fellowship: Medical Oncology
Diplomat, American Board of Internal Medicine
July 1981-June 1984
University of California, San Diego
San Diego, CA Affiliated Hospitals
Residency: Internal Medicine
Diplomat, American Board of Internal Medicine
Sept. 1977-June 1981
University of California, San Francisco
San Francisco, CA School of Medicine
M.D.
Sept. 1974-June 1977
Rutgers College New Brunswick, NJ
A.B., magna cum laude in biochemistry
PROFESSIONAL WORK HISTORY AND TEACHING EXPERIENCE:
June 15, 2005 –
Present
Professor and Chief
Bill and Louise Bauer Distinguished Chair in Cancer Research
The University of Texas Medical Branch
Department of Internal Medicine
Division of Hematology/Oncology
August 15, 2005Present
Area Medical Director, Hematology/Oncology Clinic
March 1, 2007 Present
Associate Director for Clinical Research, Comprehensive Cancer Center
1
March 1, 2007
Present
Director, Oncology Clinical Trials
February 2005 –
June 14, 2005
Visiting Professor
The University of Texas Medical Branch
Department of Internal Medicine
Division of Hematology/Oncology
301 University Blvd.
Galveston, Texas 77555-0565
May 1995 –
June 14, 2005
Director, Research and Development
Central Texas Cancer Care
St. Joseph Regional Cancer Center
2215 East Villa Maria Suite 120
Bryan, TX 77802-2548
Jan. 1998Dec. 2001
Director, Medical Oncology
College Station, TX
College Station Medical Center (CSMC)
Aug. 1987May 1995
Assistant Professor of Medicine
Houston, TX
University of Texas M.D. Anderson Cancer Center
Division of Medical Oncology
1990-1995
Assistant Internist
Houston, TX
University of Texas M.D. Anderson Cancer Center
Department of Gastrointestinal Oncology
and Digestive Diseases
1987-1990
Assistant Internist
Houston, TX
University of Texas M.D. Anderson Cancer Center
Department of Clinical Immunology and Biological Therapy
1986-1987
UCSF Cancer Research Institute
San Francisco, CA
• Clinical Instructor in Medicine
• Attending Medical Oncologist
• Assistant Director, Biologic Response Modifier Program
• Director, Cellular Immunotherapy
• Research and Clinical Laboratories
1978-1979
Research Fellow
San Francisco, CA
President’s Undergraduate Fellowship Program
UCSF School of Medicine
BOARD CERTIFICATION:
2
Board Certified in Internal Medicine:
Board Certified in Medical Oncology:
Board Recertification in Medical Oncology:
09/12/84
11/05/91
08/09/04
Expires: 12/31/2014
LICENSURE INFORMATION:
Texas H3701 expires: 2/28/2009
California G48961 expires: 4/30/2010
PROFESSIONAL AND TEACHING EXPERIENCE:
Academic:
Non-Academic:
RESEARCH ACTIVITIES:
Area of Research
Grant Support
Current
ET743-OVA-301
Johnson and Johnson Pharmaceutical Research and Development, LLC
“An Open-Label Multicenter Randomized Phase 3 Study Comparing the Combination of
DOXIL/CAELYX and YONDELIS with DOXIL/CAELYX Alone in Subjects with Advanced
Relapsed Ovarian Cancer”
Markowitz (PI)
TC $6,312
February 2006 - present
C80405
CALGB/SWOG
“C80405, A Phase III Trial of Irinotecan/5-FU/Leucovorin Or Oxaliplatin/5-FU/Leucovorin with
Bevacizumab or Cetuximab (C225) Or with the Combination of Bevacizumab and Cetuximab for
Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum”
Markowitz (Co-PI)Whitehead (PI)
$1,000 per patient
March 2006 – present
N0147
NCCTG/SWOG
“N0147, A Randomized, Phase III Trial of Oxaliplatin (OCAL) Plus 5-Fluorouracil (5FU)/Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with
Stage III Colon Cancer”
Markowitz (Co-PI)Whitehead (PI)
$1,000 per patient
March 2006 – present
DACO-016
MGI Pharma
“DACO-016: Randomized Phase 3 Trial of Decitabine Versus Patient’s a Choice with Physician’s
Advice of Either Supportive Care or Low-Dose Cytarabine for the treatment of Older Patients with
Newly Diagnoses Acute Myeloid Leukemia”
Markowitz (Co-PI) Bessman (PI)
TC $4,200 - $78,056
May 2006 – present
P06-001
Alexion Pharmaceuticals, Inc.
“Examination of PNH, by Level Of CD59 on REd and white blood cells, in bone marrow failure
syndromes (EXPLORE)”
3
Markowitz (Co-PI)Willis (PI)
TC $3,200 - $8,750
March 2007 – present
CA183002
Bristol-Myers Squibb Company
“A Multicenter, Randomized Double-Blind Phase II/III Study in the First-line Treatment of
Advanced Transitional Cell Carcinoma (TCC) of the Urothelium Comparing
Vinflunine/Gemcitabine to Placebo/Gemcitabine in Patients who are Ineligible to Receive CisplatinBased Therapy”
Markowitz (PI)
TC $11,400 - $60,950
April 2007 – present
AVF3671g
Genentech, Inc.
“A Randomized, Double-Blind, Placebo-Controlled, Phase IIIb Trial Comparing Bevacizumab
Therapy with or without Erlotinib after Completion of Chemotherapy with Bevacizumab for the
First-Line Treatment of Locally Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer”
Markowitz (Co-PI)Willis (PI)
TC $9,400 –$394,890
April 2007 – present
AN-SCD1121
Anthera Pharmaceuticals, Inc.
“IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome (Dose
Escalation Study: Varespladib Infusion [A-001] for the Prevention of Acute Chest Syndrome in AtRisk Patients with Sickle Cell Disease and Vaso-occlusive Crisis)”
Markowitz (Co-PI)Bessman (PI)
TC 8,600 - $36,469
May 2007 – present
H6Q-MC-JCBT(a)
Eli Lilly and Company
“A Phase 2 Double-Blind Randomized Study of Oral Enzastaurin HCl versus Placebo Concurrently
with Pemetrexed (Alimta®) as Second-Line Therapy in Patients with Advanced or Metastatic NonSmall Cell Lung Cancer”
Markowitz (Co-PI)Willis (PI)
TC $7,650 - $163,271
May 2007 – present
20050236
Amgen, Inc.
“A Randomized, Open-Label, Controlled, Phase II Trial of Combination Chemotherapy with or
without Panitumumab as First-Line Treatment of Subjects with Metastatic or Recurrent Head and
Neck Cancer, and Cross-over Second Line Panitumumab Monotherapy of Subjects who Fail the
Combination Chemotherapy Only Arm”
Markowitz (PI)
TC $13,280 - $80,480
June 2007 – present
AVF3991n
Genentech, Inc.
“An Observational Study of Avastin (bevacizumab) in Combination with Chemotherapy for
Treatment of Metastatic or Locally Advanced and Unresectable Colorectal Cancer, Locally
Advanced or Metastatic Non-Small Cell Lung (Excluding Predominant Squamous Cell Histology)”
Markowitz (Co-PI)Suleman (PI)
TC $4,500 – $30,000
June 2007 – present
H3E-US-S047(c)
Eli Lilly and Company
“Phase 1/2 Study of Pemetrexed (Alimta®) plus Carboplatin, or Pemetrexed plus Cisplatin with
Concurrent Radiation Therapy Followed by Every-21-Day Pemetrexed Consolidation in Patients
with Favorable-Prognosis Inoperable Stage IIIA/B Non-Small-Cell Lung Cancer (NSCLC)”
Markowitz (Co-PI)Willis (PI)
TC $6,850 - $44,650
June 2007 – present
B001
Eli Lilly and Company
“H3E-US-B001: Non-small Cell Lung Cancer: The Impact of Ethnic Origin on Patients being
Treated Second Line with Pemetrexed - An Observational Study”
4
Markowitz (Co-PI)Willis (PI)
TC $5,150 – $81,248
June 2007 – present
EPO-ANE 2007
OrthoBiotech
“A Randomized, Open Label, Comparative Study of Epoetin Alfa (PROCRIT ®) 80,000 Units or
120,000 Units Q3W Versus Darbepoetin Alfa (ARANESP ®) 500 mcg Q3W in Anemic Cancer
Subjects Receiving Chemotherapy.”
Markowitz (PI)
TC $7,000
August 2007 – present
20062088
Amgen, Inc
“Protocol 20062088: Phase 2, Single-Arm, Open-Label, Multi-Center Trial of Second-Line
Panitumumab Monotherapy in Patients with Metastatic or Recurrent Squamous Cell Carcinoma of
the Head and Neck”
Markowitz (PI)
TC $7350 - $51,470
January 2008 – present
20062079
Amgen, Inc.
“A Phase 2 Randomized Trial of Panitumumab with Radiotherapy Compared to Chemoradiation in
Unresected, Locally Advanced Head and Neck Cancer”
Markowitz (PI)
TC $10,100 - $80,000
January 2008 – present
20062080
Amgen, Inc.
“A Phase 2 Randomized Trial of Chemoradiation with or without Panitumumab in Unresected,
Locally Advanced Head and Neck Cancer”
Markowitz (PI)
TC $10,100 - $80,000
January 2008 – present
Pending
Past
May 1995 to June 15, 2005:
PI - SWOG N9831. Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel
with or without Traztuzumab as Adjuvant Treatment for Women with HER-2 Overexpressing Node Positive
Breast Cancer.
Co-PI - CTSU NSABP B-35-A. Clinical Trial Comparing Anastrozole with Tamoxifen in Postmenopausal
Patients with Ductal Carcinoma In Situ (DCIS) Undergoing Lumpectomy with Radiation Therapy.
PI - CTSU MA.27-A. A Randomized Phase III Trial of Exemestane Versus Anastrozole with or without
Celecoxib in Postmenopausal Women with Receptor Positive Primary Breast Cancer.
PI - Genentech H2757n. registHER: An Observational Cohort Study of Patients with HER2-Positive
Metastatic Breast Cancer.
Co-PI - IBCSG 25-02. A Phase III Trial Evaluating the Role of Exemestane Plus GnRH Analogue as
Adjuvant Therapy for Postmenopausal Women with Endocrine Responsive Breast Cancer.
Co-PI - SWOG S9927. Phase III Randomized Trial of Post-Mastectomy Radiotherapy in Stage II Breast
Cancer in Women with One to Three Positive Axillary Nodes.
PI - Novartis CSG 2026705024. Letrozole (Femara) Preoperative Hormone Therapy for Postmenopausal
Women with ER and/or PgR Positive Breast Cancer: A Double Blind Randomized Parallel Group Phase
IIb/III Trial, Comparing the Efficacy of 4 Months Preoperative Letrozole (2.5 mg daily) with Preoperative
Tamoxifen (20 mg daily).
5
PI - Novartis CZOL446E US32. An Open-Label, Randomized, Multicenter Study to Evaluate the Use of
Zoledronic Acid in the Prevention of Cancer Treatment-Related Bone Loss in Postmenopausal Women with
ER+ and/or PR+ Breast Cancer Receiving Letrozole as Adjuvant Therapy.
Co-PI - SWOG S0226. Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as
First Line Therapy for Postmenopausal Women with Metastatic Breast Cancer.
PI - Aventis XRP6258A (RPR 116258A)/2001. A Multicenter Phase II Randomized Study of RPR 11628
Administered as a 1-Hour Intravenous Infusion Every Three Weeks in Taxoid Resistant Metastatic Breast
Cancer Patients.
Co-PI - BCIRG 005. A Multicenter Phase III Randomized Trial comparing Docetaxel in Combination with
Doxorubicin and Cyclophosphamide vs Doxorubicin and Cyclophosphamide Followed by Docetaxel as
Adjuvant Treatment of Operable Breast Cancer in HER2NEU Negative Patients with Positive Axillary
Lymph Nodes.
PI - SWOG JMA 17. A Phase III Randomized Double Blind Study of Letrozole Versus Placebo in Women
with Primary Breast Cancer Completing Five or More Years of Adjuvant Tamoxifen.
PI - Aventis (University of Washington 02-01). Phase III Randomized Study of Three Different Doses of
Weekly Docetaxel as First-Line Treatment of Metastatic Breast Cancer.
PI - SWOG S9626. A Phase III Trial Of Placebo Versus Megestrol Acetate 20 mg/day Versus Megestrol
Acetate 40 mg/day as Treatment for Symptoms of Ovarian Failure in Women Treated for Breast Cancer.
PI - SmithKline Beecham 223030/010. A Multicenter, Randomized, Double-Blind Study of Idoxifene 40
mg/day Versus Tamoxifen 20 mg/day as First-Line Hormonal Therapy of Locally Advanced or Metastatic
Breast Cancer in post-Menopausal Women.
PI - SWOG E2496. A Randomized Phase III Trial of ABVD Versus Stanford V (±) Radiation Therapy in
Locally Extensive and Advanced Stage Hodgkin’s Disease with 0-2 Risk Factors.
PI - Genentech. The National Lymphocare Study: An Observational Study of Treatment, Outcomes and
Prognosis in Patients with Follicular Non-Hodgkin’s Lymphoma.
PI - MD Anderson CRC Campath-1H. A CRC Phase II Study of Cappath-1H in Patients with B-cell
Chronic Lymphocytic Leukemia and residual Disease after Chemotherapy.
PI - Cedars Sinai Medical Center NHL 9602. Continuous Infusion Cisplatin with sequential Fludarabine and
Ara-C Supported by Recombinant GM-CSF in Patients with Refractory Non-Hodgkin’s Lymphoma: A
Phase II Protocol.
PI - CBRG 98-07. Phase II Trials of CHOP Chemotherapy and Interferon Alpha or Rituximab Anti-CD20
Monoclonal Antibody as Initial Treatment of Patients with Stage III or IV High-Risk Indolent B-Cell and
Intermediate Grade B-Cell Lymphoma.
PI - CBRG 98-06. Patients with Chronic Lymphocytic Leukemia or Multiple Myeloma Whose Disease has
been Controlled with Chemotherapy: Rituximab Anti-CD20 Monoclonal Antibody or Interferon Alpha 2-b
as Maintenance Therapy.
PI - CBRG 98-05. Rituximab Anti-CD20 Monoclonal Antibody and Dexamethasone in the Treatment of
Relapsed Indolent Lymphoma.
6
PI - CBRG 98-01. Rituximab Anti-CD20 Monoclonal Antibody plus Oral Cyclophosphamide as Initial
Treatment of Indolent Lymphoma.
PI - Aronex 002. Phase II Study of Atragen (Liposomal-Tretinoin) in Patients with Acute Promyelocytic
Leukemia (APL) Following First or Subsequent Relapse.
PI - Aronex 005. Phase II Study of Monotherapeutic Treatment Using Atragen (Liposomal-Tretinoin) in
Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL).
PI - SWOG S0023. A Phase III Trial of Cisplatin/Etoposide/Radiotherapy with Consolidation Docetaxel
Followed by Maintenance Therapy with ZD 1839 or Placebo in Patients with inoperable Locally Advanced
Stage III Non-Small Cell Lung cancer.
PI - SWOG S9925. Lung Cancer Specimen Repository Protocol, Ancillary to S0023.
PI - Novartis CZOL446EUS99. Z-NEXT Registry. A Dual-Cohort, Prospective, Observational Registry of
Unresectable Stage IIIB/IV Non-Small Cell Lung Cancer Patients with and without Bone Metastasis.
PI - AstraZeneca 1839IL/0050. An Expanded Access Clinical Program with ZD 1839 (Iressa) for Patients
with Advanced Non-Small Cell Lung Cancer (NSCLC).
PI - Bristol-Myers Squibb B97-2250. A Multi-Center Phase II Randomized Trial for Stage IIIB or IV NonSmall Cell Lung Cancer Utilizing Taxol and Carboplatin Followed biweekly Maintenance of Taxol or
Observation.
PI - Eli Lilly 238-09-00. Gemcitabine/Carboplatin Surveillance Study in Patients with Advanced Metastatic
Non-Small Cell Lung Cancer.
PI - Bristol-Myers Squibb ACR-427. A Phase II Randomized Study of Taxol (Paclitaxel), Paraplatin
(Carboplatin), and Radiation Therapy for Locally Advanced Inoperable Non-Small Cell Lung Cancer.
PI - SWOG E4697. A Randomized, Placebo-Controlled Phase III Trial of Yeast Derived GM-CSF Plus
Peptide Vaccination Versus Placebo in Patients with “No Evidence of Disease” after Complete Surgical
Resection of Locally Advanced and/or Stage IV Melanoma.
PI - SWOG 95-196. Adjuvant Therapy for Melanoma Patients with Regional Lymph Node Metastases with
Interferon Alfa-2b vs. Biochemotherapy Using Cisplatin + Vinblastine + DTIC + Interferon plus IL-2.
PI - NBSG 92-06. The Use of Cisplatin, Adriamycin, Cytoxan, Zofran and Neupogen in Metastatic or
Recurrent Adenocarcinoma of the Endometrium.
PI - NBSG 94-14. Interferon Alfa-2a (Roferon-A) and Cisretinoic acid (Accutane) for the Treatment of
Squamous Cell Carcinoma of the Cervix.
Co-PI - SWOG GO175. Randomized Phase III Trial of IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2
q21 Days x 3 Courses plus Weekly Low Dose Paclitaxel 40 mg/m2 Versus IV Carboplatin (AUC 6) and
Paclitaxel 175 mg/m2 q21 Days x 3 Courses plus Observation in Patients with Early Stage Ovarian cancer.
Co-PI - SWOG R9811. A Phase III Randomized Study of 5-Fluorouracil, Cisplatin, and Radiotherapy vs. 5Fluorouracil, Mitomycin-C, and Radiotherapy in Carcinoma of the Anal Canal.
7
PI - MD Anderson. A Phase II Trial of Systemic Platinol, Recombinant Human Interferon Alpha (rINF2b),
Adriamycin, and 5FU (PIAF) for the Treatment of Biliary Tract Carcinoma.
PI - Eli Lilly B9E-US-S337. A Multicenter, Randomized Phase II Trial of Gemcitabine plus 5FU/Folic Acid
(FFG) Versus Oxaliplatin plus 5FU/Folinic Acid (FOLFOX 4) as Therapy for Patients with Metastatic
Colorectal Cancer.
PI - SWOG CALGB 80203. A Phase III Trial of Irinotecan/5FU/Leucovorin or Oxaliplatin/5FU/Leucuvorin
with and without Cetuximab (C225) for Patients with Untreated Metastatic Adenocarcinoma of the Colon or
Rectum.
PI - Genentech AVF 29412n. An Observational Study of Avastin (Bevacizumab) in Combination with
Chemotherapy for First-Line Treatment of Metastatic Colorectal Adenocarcinoma.
PI - SWOG C89803. A Phase III Intergroup Trial of Irinotecan plus Fluoruracil/Leucovorin (5FU/LV)
Versus Fluoruracil/Leucovorin Alone After Curative Resection for Patients with Stage III Colon Cancer.
PI - SWOG N9841. A Randomized Phase III Equivalence Trial of Irinotecan vs. Oxaliplatin/5Fluoruracil/Leucovorin in Patients with Advanced Colorectal Carcinoma Previously treated with 5-FU.
PI - SWOG E1199. A Phase III Study of Oxaliplatin (OXAL)/5-Fluorouracil (5-FU)/Leucovorin (CF) in
Patients with Advanced Colorectal Carcinoma Previously treated with 5-FU.
PI - SWOG N9741. A Randomized Phase III Trial of Combinations of Oxaliplatin (OXAL), 5-Fluorouracil
(5-FU), and Irinotecan (CPT-11) as Initial Treatment of Patients with Advanced Adenocarcinoma of the
Colon and Rectum.
PI - SWOG CALGB 80303. A Randomized Phase III Trial of Gemcitabine plus Bevacizumab Versus
Gemcitabine plus placebo in Patients with Advanced Pancreatic Cancer.
PI - Eli Lilly B9E-MC-JHEW. Treatment IND of Gemzar for Patients with Pancreatic Cancer.
PI - SWOG 9346. Intermittent Androgen Deprivation in Patients with Stage D2 Prostate Cancer- Phase III.
Co-PI - SWOG S0032. Phase II Evaluation of Early Oral Estramustine, Oral Etoposide and Intravenous
Paclitaxel in Combination with Hormone Therapy in Patients with High-Risk Metastatic Adenocarcinoma of
the Prostate.
PI - Eli Lilly. Phase II Trial of Weekly Paclitaxel in Patients with Previously Treated Advanced Urothelial
Cancer.
PI - SWOG S0007. Evaluation of 3 Hour Infusion of Paclitaxel plus Cisplatin and 5-Fluorouracil in Patients
with Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN).
`
Co-PI - MedImmune. Open label Prospective Trial Evaluating the Toxicities Associated with Subcutaneous
Administration of Ethyol (Amifostine) for the Prevention of radiation-Induced Toxicities.
PI - IOSG- GPT-ST1. Gemcitabine (Gemzar), Cisplatin (Platinol), and Docetaxel (Taxotere) in the
Treatment of Patients with Refractory Solid Tumors.
PI - NBSG 95-08. Interferon Alfa-2a (Roferon), Cis-retinoic Acid (Accutane) and Radiation Therapy in the
Primary Treatment of High Grade Gliomas.
8
PI - Novartis CSMS995AUS38. Sandostatin LAR Depot Trial for the Optimum Prevention of
Chemotherapy Induced Diarrhea. A Multi-Center, Randomized Phase IV Trial.
PI - Ortho McNeil CAPSS-078. Multicenter, Randomized Study to Compare the Safety and Efficacy of Oral
Levofloxacin vs. Parenteral Ceftriaxone and Amikacin with the Potential of Conversion to Oral
Ciprofloxacin and Amoxicillin/Clavulanate in the Treatment of Subjects with Talcott Group IV Febrile
Neutropenia.
PI - Knoll VP-42. A Double-Blind, Randomized, Parallel Study to Evaluate the Efficacy and Safety of
Vicoprofen (Hydrocodone Bitartrate with Ibuprofen) vs. Oxycodone HCL with Acetaminophen in Patients
with Cancer Pain.
PI - MedImmune. A Randomized Multicenter trial Comparing Ethyol to No Treatment for Preventing
Progressive Peripheral Neuropathy in Platinum-Based Chemotherapy Regimens.
PI - Wyeth. Prospective Observational Study of Neumega (Oprelvekin) in Usual Care.
PI - Amgen Neulasta (pegfilgrastim) 20020122. A Randomized, Open Label, Multicenter Study of Primary
Prophylaxis with Neulasta (pegfilgrastim) Versus Secondary Prophylaxis as an Adjunct to Chemotherapy in
Elderly Subjects (>65 years old) with Cancer.
PI - Amgen Darbepoietin alfa 20020139. A Randomized, Open-Label Study to Assess Time to Hemoglobin
Response of a Front Load dosing regimen for darbepoietin alfa Compared to a Weekly Dose regimen for
Recombinant Human Erythropoietin in Patients with Non-myeloid Malignancies Receiving Chemotherapy.
PI - Ortho Biotech PR03-27-064 Phase IIb. A Randomized, Open-Label Study of Procrit (Epoietin alfa)
Initiated at 40,000 Units Every Week Versus 80,000 Units Every two Weeks in Anemic Patients with Cancer
Receiving Chemotherapy.
PI - Ortho Biotech PR02-27-018. Retrospective Review of Alternate Procrit Dosing in Patients with
Chemotherapy related Anemia.
PI - Ortho Biotech PR02-27-016. An Open-Labeled Pilot Study to Evaluate the Effects of High Dose Procrit
(Epoietin alfa) in Maintaining Hemoglobin Levels in Anemic Cancer Patients Receiving Chemotherapy on a
Every 3 Week regimen.
PI - Ortho Biotech PR02-27-015. An Open-Labeled Pilot Study to Evaluate the Effects of High Dose Procrit
(Epoietin alfa) in Maintaining Hemoglobin Levels in Anemic Cancer Patients Receiving Chemotherapy on a
Weekly or Every 4 Week regimen.
PI - Ortho Biotech PR02-27-011. A Pilot Study to Evaluate the Response Rate to Procrit (Epoietin alfa) at
40,000 Units Once Weekly in Anemic Cancer Patients Not Receiving Chemotherapy or Radiotherapy.
PI - Ortho Biotech PR98-03-018. Clinical Evaluation of Once Weekly Dosing of Procrit (Epoietin alfa) in
Anemic Cancer Patients Receiving Radiation Therapy Either Concomitantly or sequentially with
Chemotherapy.
PI (effective 07/08/05) – “NSABP B-27: A Randomized Trial Comparing Preoperative Doxurobicin
Adriamycin) Cyclophosphamide (AC) to Pre-oprative AC followed by Docetaxel (Taxotere) and to
Preoperative AC followed by Postoperative Docetaxel in Patients with Operable Carcinoma of the Breast”,
August 1998 – present.
9
PI (effective 08/04/05) – “A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects with Advanced
Primary Carcinoma of the Liver,” PI-initiated protocol, October 2004-present.
COMPLETED – PAST 6/16/05 - Current
RC-1291-205
Sapphire Therapeutics, Inc.
“A Twelve-Week, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Phase II Study of
the Safety and Efficacy of RC-1291 HCl in Patients with Cancer Anorexia/Cancer with a FourWeek-Open-Label Extension,”
Markowitz (PI)
TC $5,150
May – July 2006
RC-1291-203
Sapphire Therapeutics, Inc.
“A Two-Part Phase II Study of the Effects of RC-1291 HCL in Patients with Cancer
Anorexia/Cachexia: An Inpatient Crossover Study of the Appetite-Enhancing and Biochemical
Effects of RC-1291 HCL followed by an Outpatient Parallel Group Study of the Effects of RC-1291
HCL on Body, Weight, Body Composition and Functional Performance”
Markowitz (PI)
TC $11,325
October 2005 - July 2006
2005-10-003
Exagen Diagnostics, Inc.
“Validation of Key2 Breast Cancer Hormone Receptor Positive (Key2HR+) and Key2 Breast Cancer
Hormone Receptor Negative (Key2 HR-) Tests for Estimating Likelihood of Distant Recurrence in
Invasive Ductal Carcinoma”
Markowitz (PI)
TC $70,463
March 2006 – April 2007
RC-1291-206
Sapphire Therapeutics, Inc.
“A Twelve-Week, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Phase II Study
Comparing the Safety, Tolerability and Beneficial Effects of Daily Doses of 100 mg and 50 mg of
RC-1291 HCl and Placebo in Patients with Cancer Anorexia/Cachexia”
Markowitz (PI)
TC $31,629
August 2006 – August 2007
COMMITTEE RESPONSIBILITIES:
International
National
State/Regional
UTMB
July 1, 2005 – Present
September 2005 – Present
December 2005 – Present
December 2005 – 2007
January 2006 – 2007
April 2006 – 2007
August 2006 – 2007
March 2007 – Present
March 2007 – Present
Committee Member, Graduate Medical Education Committee
Committee Member, Pharmacy & Therapeutics Committee
Search Committee, for Chairman of Department of Radiology
Committee Member, Joint Clinical Enterprise Research and
Education Committee
Committee Member, Special Task Force for Interventional
Radiology Section in the Department of Radiology and the
Department of Medical Management
Faculty Group Practice Executive Committee
Community Physician Partnerships” Committee
Cancer Center Membership Committee
Director, UTMB Clinical Trials Office (OCTO)
10
March 2007 – Present
September 2006 – Present
January 2008 - Present
February 2008 – Present
Associate Director for Clinical Research, UTMB Comprehensive
Cancer Center
Cancer Patient Acceptance Committee
Chair, Cancer Committee
Pain Medicine Fellowship Multidisciplinary Committee
School
Departmental
Other
COLLEGE STATION MEDICAL CENTER
1997-2005
1997-2001
Member, Cancer Committee
Chairman, Cancer Committee
ST. JOESEPH REGIONAL CANCER CENTER
1997-2005
1995-2005
1997-2005
1995-2005
1995-2005
Member, Blood Usage Review Committee
Director, Tumor Conference
Chairman, Pharmacy and Therapeutics Committee
Member, Cancer Committee
Member, Pharmacy and Therapeutics Committee
MD ANDERSON CANCER CENTER
1993-1995
1993-1995
1993-1995
1992-1995
1992-1995
1991-1995
1990-1994
1992-1994
1991-1993
1990-1992
1990-1991
1989-1991
1988-1991
Chairman, Clinical Pertinence Subcommittee
Member, Medical Records Committee
Member, Desktop Information Standards Task Force
Member, Computer Based Patient Record Steering Committee
Vice-Chairman, Pharmacy and Therapeutics Committee
Member, Pharmacy and Therapeutics Committee
Member, Surveillance Committee
Member, Database Master Plan Committee
Member, Research Medical Library Advisory Committee
Chairman, SMS Computerization Committee
Member, Utilization Committee
Vice-Chairman, Medical Records Committee
Member, Medical Records Committee
UNIVERSTIY OF CALIFORNIA, SAN FRANCISCO
1986-1987
1986-1987
1986-1987
1986-1987
1984-1987
Attending Oncologist, Biologic Response Modifiers Clinic
Attending Oncologist, General Oncology Clinic
Attending Oncologist, Head and Neck Tumor Board
Attending Oncologist, Gynecologic Oncology Tumor Board
Cancer Research Institute Grand Rounds twice yearly
Cancer Research Institute Journal Club 4-6 times yearly
Professional Education Committee, ACS, California Division
1995-2005
1995-2005
Member, Steering Committee, American Cancer Society, Brazos County
National Melanoma Faculty
11
1994-2005
1991-2005
1998-2000
1997-2000
1993-1994
Visiting Faculty in Interferons
Expert Panel, Texas Research Oncology Network
Board of Directors, Cancer Biotherapy Research Group
Cancer Liaison Physician of the Commission on Cancer, American College of
Surgeons
National Faculty Member, Consultant Care Network
COMMUNITY ACTIVITIES
Board of Director, Cancer Society Brazos Valley Unit
Opera Performing Arts Society
Member, Chamber of Commerce
Participant of the Cancer Survivor Day Program
Participant for the Cancer Relay for Life
Sponsor, Cancer Fashion Show
College Station, Texas
College Station, Texas
College Station, Texas
College Station, Texas
College Station, Texas
College Station, Texas
TEACHING RESPONSIBILITIES:
A.
TEACHING RESPONSIBILITES AT UTMB:
July 2005–Present
Director of Medical Oncology Fellowship Program
February 13, 2006
Pathobiology & Host Defense (PHD) 2005-06 Course in the Integrated (One hour
lecture) Medical Curriculum “Principles of Cancer Treatment II”
June 29, 2007
Internal Review Process for the ACGME Institutional Review for General
Preventive Medicine.
MEMBERSHIP IN SCIENTIFIC SOCIETIES:
American Association for the Advancement of Science
American College of Physicians
American Medical Association
American Society of Clinical Oncology
American Society of Hematology
American Society for Therapeutic Radiology and Oncology
Brazos-Robertson County Medical Society
M. D. Anderson Associates
Southern Association for Oncology
Southern Medical Association
Texas Medical Association
Texas Society of Medical Oncology
HONORS:
2002-2003
1977-1978
1977
Physician of the Year: American Cancer Society, Brazos County
President's Undergraduate Fellow: UCSF School of Medicine
Phi Beta Kappa: Rutgers College
Joseph J. Polonko, Jr. Memorial Scholarship: Rutgers College
12
ADDITIONAL INFORMATION:
Editorial Boards:
1994-present
1990-present
PDQ External Advisory Board (National Cancer Institute)
Journal of Cancer Research and Clinical Oncology
Meeting Sponsorship:
January 1998
Therapeutic Options in Cancer:
Bi-Annual Meeting of the Cancer Biotherapy Research Group
College Station, Texas
Accreditation:
January 13 – May 20, 2006
Certificate in Medical and Health Management
Rice University, Houston, Texas
October 17 - 18, 2007
Leadership Training Session by the Studer Group – Taking You and Your
Organization to the Next Level with Quint Studer, Nashville, TN
Poster Reviews:
April 26, 2007 National Student Research Forum (NSRF) Oncology Poster Session Judge. University of
Texas Medical Branch, Galveston, Texas
PUBLISHED:
A.
ARTICLES IN PEER-REVIEWED JOURNALS:
1.
Dutcher JP, Creekmore S, Weiss GR, Margolin K, Markowitz AB, Roper MA, Parkinson D,
Ciobanu N, Fisher RI, Boldt DH, Doroshow JH, Rayner AA, Hawkins M, Atkins M. A phase II
study of interleukin-2 and lymphokine activated killer (LAK) cells in patients with metastatic
malignant melanoma. J Clin Oncol 4: 477-485, 1989.
2.
Parkinson DR, Talpaz M, Lee KH, Legha S, Markowitz AB, Itoh K, Balch CM, Murray JL,
Zukiwski AA, Benjamin RS, Gutterman JU. Interleukin-2 alone and in combination with other
cytokines in melanoma: The investigational approach at the University of Texas M. D. Anderson
Cancer Center. Cancer Treat Rev 16: 39-48, 1989.
3.
Hudson MM, Markowitz AB, Gutterman JU, Knowles RD, Snyder JS, Kleinerman ES. Effect of
recombinant human interleukin 4 on human monocyte activity. Cancer Res 50: 3154-3158, 1990.
4.
Neefe JR, Legha SS, Markowitz A, Salmon S, Meyskens F, Groopman J, Campion M, Evans L.
Phase II study of recombinant -interferon in malignant melanoma. Am J Clin Oncol 13: 472-476,
1990.
5.
Itoh K, Balch CM, Murray JL, Parkinson DR, Markowitz AB, Talpaz M, Lee K, Zukiwski AA, Ross
MI, Legha SS, Hayakawa K, Salmeron MA, Augustus LB. Immunological properties of melanoma
tumor-infiltrating lymphocytes before and after IL-2-based biotherapies. In Vivo 5: 647-654, 1991.
13
6.
Hayakawa K, Salmeron MA, Parkinson DR, Markowitz AB, von Eschenbach AC, Legha SS, Balch
CM, Ross MI, Augustus LB, Itoh K. Immunological study of interleukin-2 activated tumorinfiltrating lymphocytes for adoptive cellular therapy for human metastatic melanoma and renal cell
carcinoma. J Immunother 10: 313-325, 1991.
7.
Freimann JH and Markowitz AB. Cytokines and chemotherapy: A new approach to therapy for
solid tumors. Cancer Bull 43: 224-232, 1991.
8.
Schilling P, Murray JL, Markowitz AB. Novel tumor necrosis factor toxic effects: Pulmonary
hemorrhage and severe hepatic dysfunction. Cancer 69: 256-60, 1992.
9.
Wetzler M, Estrov Z, Talpaz M, Markowitz A, Gutterman JU, Kurzrock R. Granulocytemacrophage colony-stimulating factor as a cause of paraneoplastic leukemoid reaction in advanced
transitional cell carcinoma. J Int Med 234: 417-420, 1993.
10.
Ajani JA, Abbruzzese JL, Markowitz AB, Patt YZ, Daugherty K. Phase II study of etoposide and
alpha-interferon in patients with advanced measurable colorectal carcinoma. Invest New Drugs 11:
67-69, 1993.
11.
Dimopoulos MA, Logothetis CJ, Markowitz A, Sella A, Amato R, Ro J. Collecting duct carcinoma
of the kidney. Brit J Urol 71: 388-391, 1993.
12.
Danhauser LL, Freimann JH, Gilchrist TL, Gutterman JU, Hunter CY, Yeomans AC, Markowitz
AB. Phase I and plasma pharmacokinetic study of infusional 5-fluorouracil combined with
recombinant interferon alfa-2b in patients with advanced cancer. J Clin Oncol 11: 751-761, 1993.
13.
Kirk IR, Carrasco CH, Lawrence DD, Chuang VP, Richli WR, Charnsangavej C, Kavanagh JJ,
Kudelka AP, Freedman RS, Markowitz AB. Intraperitoneal catheters: Percutaneous placement with
fluoroscopic guidance. JVIR 4: 299-304, 1993.
14.
Estrov Z, Markowitz AB, Kurzrock R, Wetzler M, Kantarjian HM, Ferrajoli A, Gutterman JU,
Talpaz M. Suppression of chronic myelogenous leukemia colony growth by interleukin-4.
Leukemia 7: 214-220, 1993.
15.
Sella, Swanson DA, Ro JY, Putnam JB, Amato RJ, Markowitz AB, Logothetis CJ. Surgery
following response to interferon- -based therapy for residual renal cell carcinoma. J Urol 149: 1922, 1993.
16.
Pazdur R, Lassere Y, Rhodes V, Ajani JA, Sugarman SM, Patt YZ, Jones DV, Markowitz AB,
Abbruzzese J, Bready B, Levin B. Phase II trial of uracil and tegafur plus oral leucovorin: an
effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 12: 22962300, 1994.
17.
Kurzrock R, Cohen PR and Markowitz A. Clinical manifestations of vasculitis in patients with solid
tumors: A case report and review of the literature. Arch Int Med 154: 334-340, 1994.
18.
Jones DV, Sugarman SM, Markowitz AB, Levin B, Abbruzzese JL, Evans DB, Charnsangavej C,
Smith R, Patt YZ. Cisplatin, 5-fluorouracil, and leucovorin in the therapy of adenocarcinomas of the
pancreas. Oncology Reports 2: 1121-1123, 1995.
19.
Pazdur R, Bready B, Ajani JA, Abbruzzese JL, Markowitz A, Sugarman S, Jones D, Levin B. Phase
II trial of isotretinoin and recombinant interferon alfa-2a in metastatic colorectal carcinoma. Am J
Clin Oncol 18: 436-438, 1995.
14
20.
Jones DV, Lozano R, Hoque A, Markowitz A, Patt YZ. Phase II study of paclitaxel therapy for
unresectable biliary tree carcinomas. J Clin Oncol 14: 2306-2310, 1996.
21.
Patt YZ, Jones DV, Hoque A, Lozano R, Markowitz A, Raijman I, Lynch P, Charnsangavej C.
Phase II trial of intravenous fluorouracil and subcutaneous interferon alfa-2b for biliary tract cancer.
J Clin Oncol 14: 2311-2315, 1996.
22.
Khuri FR, Fossella FV, Lee JS, Murphy WK, Shin DM, Markowitz AB, Glisson BS. Phase II trial
of recombinant interferon alfa-2a with etoposide/cisplatin induction and interferon/megestrol acetate
maintenance in extensive small cell lung cancer. J Interferon and Cytokine Res 18: 241-45, 1998.
23.
Ravandi-Kashani F, Cortes J, Cohen P, Talpaz M, O’Brien S, Markowitz A, Kantarjian H.
Cutaneous ulcers associated with hydroxyurea therapy in myeloproliferative disorders. Leuk
Lymphoma 35 (1-2): 109-18, 1999.
24.
Vaughn DJ, Broome CM, Hussain M, Gutheil JC, Markowitz AB. Phase II trial of weekly paclitaxel
in patients with previously treated advanced urothelial cancer. J Clin Oncol 20: 937-940, 2002.
25.
Rao N, Sanguineti G, Chaljub G, Newlands S, Markowitz A, Pena J. Neck levels that are negative
on initial CT do not need to be dissected. International Journal of Radiation Oncology Biology
Physics 66 (3): S428-S428 2393 Suppl. S, 2006
B.
OTHER:
Letters
1.
Vassilopoulou-Sellin R, Thielvoldt D, Markowitz AB. Effects of interleukin-4 administration on
endocrine function and lipid profile of patients with malignant diseases. Blood 87: 4022-4023, 1996.
C.
ABSTRACTS:
1.
Friedman M, Lagios M, Markowitz A, Jones H, Resser K, Hoffman P. Estradiol(ER) and
Progesterone Receptors (PR) in Ovarian Cancer-Clinical and Pathological Correlation. Clinical
Research: 385A, 1979.
2.
Dutcher JP, Creekmore S, Weiss GR, Margolin K, Markowitz AB, Roper MA, and Parkinson D, for
the NCI Extramural IL-2/LAK Working Group. Phase II study of high dose Interleukin-2 (IL-2) and
lymphokine activated killer (LAK) cells in patients (pts) with melanoma. Proc Am Soc Clin Oncol 6:
246A, 1987.
3.
Markowitz AB, Fendly BM, Lile JD, Iglewski BH, Larrick JW. Production and characterization of
monoclonal antibodies to Pseudomonas aeruginosa exoenzyme S. Clinical Research: 428A, 1987.
4.
Markowitz A, Kleinerman E, Hudson M, Itoh K, LaPushin R, Stewart M, Gutterman J. Phase I study
of recombinant human interleukin-4 (rhuIL-4) in patients with advanced cancer. Blood 74: 540A,
1989.
5.
Markowitz A, Talpaz M, Lee K, Parkinson D, Doig R, Rothberg J, Levitt D, Gutterman J. Phase I-II
study of recombinant interleukin-2 (rIL-2) plus recombinant interferon- 2A (rIFN- ) in renal cell
carcinoma (RCC). Proc Am Soc Clin Oncol 8: 146A, 1989.
15
6.
Markowitz A, Parkinson D, Miller L, Levitt D, Saks S, Gutterman J. Phase I study of recombinant
interleukin-2 (rIL-2) and recombinant tumor necrosis factor (rTNF). Proc Am Soc Clin Oncol 8:
195A, 1989.
7.
Freimann J, Estrov Z, Itoh K, O’Brien S, Kantarjian H, Keating M, Yeomans A, Hunter C,
Gutterman J, Markowitz A. Phase I studies of recombinant interleukin-4 (IL-4) in patients (pts) with
hematologic malignancies. Blood 76: 361A, 1990.
8.
Markowitz A, Yeomans A, Freimann J, Hunter C, Levin B, Pazdur R, Gutterman J. Phase I study of
recombinant interferon-alpha 2A (rIFN- ), recombinant interleukin-2 (rIL-2), and 5-fluorouracil (5FU) in gastrointestinal (GI) malignancies. Proc Am Soc Clin Oncol 9: 460A, 1990.
9.
Freimann J, Markowitz A, Yeomans A, Hunter C, Danhauser L, Gutterman J. Phase I study of
recombinant interferon-alpha 2b (rIFN- ) plus infusional 5-fluorouracil (5-FU) in advanced cancer.
Proc Am Soc Clin Oncol 9: 746A, 1990.
10.
Swanson D, Markowitz A, Wishnow K, von Eschenbach A, Quesada J, Logothetis C. Primary
biological therapy with delayed radical nephrectomy for patients with metastatic renal cell
carcinoma. J Urol 143: 419A, 1990.
11.
Gressot L, Pazdur R, Markowitz A, Abbruzzese J, Faintuch J, Patt Y, Ajani J, Edwards C, Levin B,
Gutterman J. Phase I-II study of recombinant interleukin-2 (rIL-2) and fluorouracil (5-FU) plus
folinic acid (FA) for patients with advanced colorectal carcinoma. Proc Am Soc Clin Oncol 9: 457A,
1990.
12.
Pazdur R, Abbruzzese J, Faintuch J, Ajani J, Patt Y, Jackson D, Markowitz A, Winn R, Gutterman J,
Levin B. Phase II study of recombinant interferon alpha (rIFN) and 5-fluorouracil (5-FU) in patients
(pts) with advanced colorectal carcinoma. Proc Am Soc Clin Oncol 9: 455A, 1990.
13.
Itoh K, Parkinson D, Salmeron M, Hayakawa K, Morita T, Augustus L, Markowitz A, Mansfield P,
Ross M, Legha S, Von-Eschenbach A, Balch C. Study for adoptive immunotherapy of tumors with
tumor infiltrating lymphocytes (TIL). J FASEB (4): 2022A, 1990.
14.
Freimann J, Markowitz A, Yeomans C, Hunter C, Gutterman J. Phase I study of recombinant
interferon-alpha 2b (rIFN-A) and 5-fluorouracil (5-FU) infusion in disseminated cancer. Proceedings
of NCI symposium: Combining Biological Response Modifiers with Cytotoxics in the Treatment of
Cancer: 11A, 1990.
15.
Markowitz A, Yeomans A, Freimann J, Hunter C, Levin B, Pazdur R, Gutterman J. Phase I study of
recombinant interferon-alpha 2A (rIFN- ), interleukin-2 (rIL-2), and 5-fluorouracil (5-FU) in
gastrointestinal (GI) malignancies. Proceedings of NCI symposium: Combining Biological
Response Modifiers with Cytotoxics in the Treatment of Cancer: 16A, 1990.
16.
Ferrajoli A, Talpaz M, Markowitz AB, Wetzler M, Kurzrock R, Kantarjian H, Harris D, Blake M,
Gutterman JU, Estrov Z. Divergent effect of interleukin-4 (IL-4) on chronic myelogenous leukemia
(CML), acute myeloblastic leukemia (AML) and normal marrow progenitor proliferation. Blood 78:
1517A, 1991.
17.
Markowitz A, Lee KH, Doig R, Yeomans A, Parkinson D, Itoh K, von Eschenbach A, Balch C,
Gutterman J, Talpaz M. Recombinant interleukin-2 (IL-2) plus recombinant interferon- (IFN) in
solid tumors: The M. D. Anderson experience. Proc 49th Nordic Conference of Medicine and
Radiology: 73A, 1991.
16
18.
Markowitz A, Parkinson D, Itoh K, Legha S, von Eschenbach A, Logothetis C, Yeomans A,
Thielvoldt D, Kilbourn M, Hunter C, Gutterman J, Balch C. Phase IB study of tumor infiltrating
lymphocytes (TIL) combined with recombinant interferon- 2a (rIFN- ), recombinant interleukin-2
(rIL-2), and cyclophosphamide (CYC) in patients (pts) with advanced renal cell carcinoma (RCC)
and malignant melanoma (MM). Proc Am Soc Clin Oncol 10: 726A, 1991.
19.
Freimann J, Markowitz A, Yeomans A, Hunter C, Gutterman J. Phase I study of recombinant human
interferon- 2b (IFN) plus 5-fluorouracil (5-FU) as a 120 hour infusion in patients (pts) with nongastrointestinal (GI) malignancies. Proc Am Soc Clin Oncol 10: 725A, 1991.
20.
Freimann J, Estrov Z, Itoh K, Talpaz M, Estey E, Kantarjian H, Keating M, O’Brien S, Hunter C,
Gutterman J, Markowitz A. Phase I studies of recombinant human interleukin-4 (IL-4). Proc Am Soc
Clin Oncol 10: 724A, 1991.
21.
Itoh K, Markowitz AB, Hayakawa K, Salmeron MA, von Eschenbach AC, Balch CM, Parkinson
DR, Legha SS, Ross MI, Morita T, Augustus LB. Study of adoptive therapy with tumor-infiltrating
lymphocytes (TILs). Proc Am Assoc Can Res 32: 1483A, 1991.
22.
Danhauser L, Gilchrist T, Freimann J, Markowitz A, Yeomans A, Hunter C, Gutterman J. Effect of
recombinant interferon- 2b on the plasma pharmacokinetics of fluorouracil in patients with
advanced cancer. Proc Am Assoc Can Res 32: 1052A, 1991.
23.
Sella A, Logothetis CJ, Swanson D, Ro J, Dexeus F, Amato R, Kilbourn R, Markowitz A, Putnam
JB, El-Naggar A. Surgery following response for residual renal cell carcinoma after response to
interferon- (IFN ) based therapy. J Urol 145: 242A, 1991.
24.
Markowitz A, Thielvoldt D, Yeomans A, Rubenstein E, Escalante C, Freimann J, Hunter C,
Gutterman J. Beneficial effects of intracavitary interferon- 2b (IFN): A phase I study of patients
(PTS) with ascites (A) or pleural effusion (PE). Proc Am Soc Clin Oncol 11: 841A, 1992.
25.
Markowitz A, Thielvoldt D, Yeomans A, Levin B, Hunter C, Gutterman J. Phase I study of
intraperitoneal (IP) interferon- (IFN- ) and tumor necrosis factor (TNF) in patients (PTS) with
advanced intra-abdominal cancer. Proc Am Soc Clin Oncol 11: 842A, 1992.
26.
Glisson BS, Markowitz AB, Mortensen T. Phase II trial of etoposide (E)/cisplatin (P)/interferon
alpha (IFN) induction and interferon alpha/megace (M) maintenance in extensive small cell lung
cancer (ESCLC). Proc Am Soc Clin Oncol 11: 1058A, 1992.
27.
Markowitz AB, Thielvoldt D. Intracavitary interferon- 2b is highly active against malignant
effusions. Proc Am Assoc Can Res 34: 1303A, 1993.
28.
Glisson BS, Palmer JL, Shin DM, Wester M, Markowitz AB. Phase II trial of interferon alfa (IFN) +
etoposide/cisplatin (EP) induction and IFN/Megace (M) maintenance in extensive small cell lung
cancer (ESCLC). Proc Am Soc Clin Oncol 12: 1194A, 1993.
29.
Markowitz A, Mavligit G, Thielvoldt D. Phase I study of hepatic arterial infusion (HAI) of
interleukin-4 (IL-4). Proc Am Assoc Can Res 35: 3112A, 1994.
30.
Markowitz A, Thielvoldt D, Patt Y, Sugarman S, Jones D, Pazdur R, Abbruzzese J, Levin B.
Prolonged continuous intravenous infusion (CIVI) fluorouracil (5-FU) plus daily subcutaneous (sc)
interferon-a2b (IFN) has activity in patients (pts) with colorectal cancer (CRC) who have failed prior
5-FU: results of a phase I-II study. Proc Am Soc Clin Oncol 13: 682A, 1994.
17
31.
Jones DV, Jr., Sugarman S, Markowitz A, Levin B, Abbruzzese JL, Patt YZ. A phase I-II study of
amiodarone (AM) and doxorubicin (DOX) for patients (pts) with advanced colorectal cancer (CRC).
Proc Am Soc Clin Oncol 13: 688A, 1994.
32.
Sugarman SM, Pazdur R, Brown C, Vosika GJ, Jones DV, Markowitz A, Ajani JA, Bready B, Soo
E, Levin B. A phase II trial of Immther for previously untreated patients (pts) with metastatic
colorectal cancer (CRC) to the liver. Proc Am Soc Clin Oncol 13: 687A, 1994.
33.
Pazdur R, Rhodes V, Lassere Y, Bready B, Soo E, Ajani JA, Abbruzzese JL, Sugarman S, Jones D,
Markowitz A, Ho D, Levin B. UFT plus leucovorin: a potentially effective oral regimen in colorectal
carcinoma. Proc Am Soc Clin Oncol 13: 590A, 1994.
34.
Markowitz AB. Interleukin-4 (IL-4) in cancer and bone marrow failure. Cancer Investigation 12
(S1): 4A, 1994.
35.
Hoque A, Chase J, Lozano R, Markowitz A, Jones DV, Carrasco H, Roh MS, Curley SA, Patt YZ.
Educating patients on hepatic arterial infusion (HAI) as an option for treatment of hepatocellular
carcinoma (HCC) and colorectal cancer metastatic to the liver. J Cancer Ed 10 (S): 32A, 1995.
36.
Patt YZ, Jones D, Markowitz A. Phase II trial of 5-FU and alpha-interferon in biliary tract cancers
(BT). Proc Am Soc Clin Oncol 14: 490A, 1995.
37.
Patt YZ, Hoque A, Jones D, Markowitz A. Phase II trial of cisplatinum, 5-FU, and leucovorin (PFL)
for primary duodenal carcinoma (PDC). Proc Am Soc Clin Oncol 14: 562A, 1995.
38.
Abbruzzese JL, Evans D, Gravel D, Markowitz A, Patt Y, Pazdur R. Docetaxel (D), a potentially
active agent for patients with pancreatic adenocarcinomas (P). Proc Am Soc Clin Oncol 14: 561A,
1995.
39.
Montoya ME, Markowitz AB, Klementich F, Palacio D. Docetaxel and fluid retention: Use of
single-dose dexamethasone. (abstract) Journal of Clinical Oncology. Accepted for presentation
at the 43rd Annual Meeting of the American Society of Clinical Oncology June 1-5, 2007.
PUBLICATIONS - IN PRESS:
ABSTRACTS
1.
Reddy NK, Markowitz, AB, Abbruzzese JL, Bhutani M. Knowledge of Indications and Utilization
of EUS: Survey of Oncologists in the USA.(abstract) Am J of Gastroenterol. (In press 2007).
Accepted for presentation at the Annual Meeting of Am College of Gastroenterology in Las Vegas
October 20, 2006.
2.
Gupta P, Tarcin O, Zwischenberger JB, Chaya C, Willis M, Markowitz AB, Kessel IL, Sharma G,
Bhutani M. Utility of JAVA based software for computer-aided EUS differentiation of benign and
malignant lymph nodes in lung cancer.(Abstract) Am J Gastroenterol. (In press 2007)
Accepted for presentation at the Annual Meeting of Am College of Gastroenterology in Las Vegas
October 20, 2006.
PUBLICATIONS – SUBMITTED:
18
1.
Raji MA, Barnum P, Freeman J, Markowitz A. Mirtazapine for depression and co-morbidities in
older cancer patients. Annals of Pharmacotherapy. Submitted. 2007
2.
Bidyasar S, Montoya M, Suleman K, Markowitz A. Sweet Syndrome Associated with G-CSF:
Treatment with Low Dose Steroids. Journal of Clinical Oncology. Submitted January 2008
INVITED LECTURES:
1.
Biologic Based Therapy of Cancer and Intraperitoneal Therapy of Ovarian Cancer
Sutter Memorial Hospital Sacramento, California. May and June 1987
2.
Interferon Therapy of Malignant Melanoma Symposium: Current Role and Future Direction of
Interferon Therapy for Dermatologic Neoplasia Stanford University Medical Center Palo Alto,
California. November 1987
3.
An Overview of Interferon in Treatment of Malignancies. Mercy San Juan Hospital
Sacramento, California. November 1987
4.
Update on Studies of Interferon- + Interleukin-2. M. D. Anderson ASCO CCOP Update
New Orleans, Louisiana. June 1988
5.
Interferon- in Renal Cell Carcinoma. University of Texas Medical Branch
Galveston, Texas. October 1988
6.
Experience with Interleukin-2 Symposium: Innovations in Urologic Practice: 1989 Baylor College
of Medicine Houston, Texas. February 1989
7.
Interferon and Biologic Response Modifiers in Melanoma Symposium: Advances in the Biological
Therapy of Cancer University of North Carolina at Chapel Hill Tampa Bay, Florida. March 1989
8.
Biologic Based Therapy of Melanoma Piedmont Oncology Association The Bowman Gray School
of Medicine Wake Forest University Winston-Salem, North Carolina. April 1989
9.
Interleukin-2 Based Therapy of Solid Tumors Florida Society of Clinical Oncology and Florida
Radiological Society Orlando, Florida. September 1989
10.
Biologic Therapy of Cancer University of Alabama, Birmingham Birmingham, Alabama.
September 1989
11.
Overview of Biologic Therapy in Cancer Humana Hospital, Sunrise Las Vegas, Nevada. September
1989
12.
Interferon- + 5-FU in the Treatment of Solid Tumors Symposium: Update on Medical Therapy of
Gastrointestinal Tumors University of Innsbruck Innsbruck, Austria. July 1990
13.
Interferons and Interleukins: Therapy into the 90’s Children's Hospital of San Francisco San
Francisco, California. July 1990
14.
Overview of Interferons Veterans Administration Medical Center Hampton, Virginia. September
1990
19
15.
Interferon- + 5-FU in the Treatment of Solid Tumors Phoenix Oncology Society Phoenix, Arizona.
October 1990
16.
Interferon- in Malignant Melanoma Symposium: Interferon in the 90’s: Decade of Decision
University of Arizona and University of North Carolina Chapel Hill Phoenix, Arizona. October
1990
17.
Interferon- + IL-2 in the Treatment of Renal Cell Carcinoma and InterferonTreatment of Solid Tumors Cleveland Clinic. Cleveland, Ohio. January 1991
18.
Placement of Interferon-
19.
The Role of Biological Response Modifiers in Solid Tumors Royal Victoria Hospital Montreal,
Canada. April 1991
20.
Interferon- , Interleukin-2, and Interleukin-4 in Solid Tumors Ottawa General Hospital Regional
Cancer Center Ottawa, Canada. April 1991
21.
Update on Therapy With InterferonCalifornia. May 1991
22.
Recombinant Interleukin-2 Plus Recombinant Interferon- in Solid Tumors: The M. D. Anderson
Experience. 49th Nordic Conference of Medicine and Radiology Tampere, Finland Westlake
Village, California. June 1991
23.
Update on InterferonSeptember 1991
24.
Update on New Regimens in Treating Colon Cancer Michigan Society of Hematology and Oncology
Dearborn, Michigan. September 1991
25.
5-FU Plus InterferonOctober 1991
in Colon Cancer University of California at Irvine Irvine, California.
26.
5-FU Plus Interferon-
in Solid Tumors University of Toronto Toronto, Canada. October 1991
27.
Treatment Update for Colorectal/GI Cancers Cancer Center of Hawaii Honolulu, Hawaii. March
1992
28.
5-FU Plus Interferon-
29.
New Therapeutic Options for InterferonIstanbul, Turkey. April 1993
30.
Interferon- : Established Role in Cancer Therapy and Future Options Innovations in Cancer
Management Conference Istanbul, Turkey. April 1993
31.
Biologic Based Therapy of Renal Cell Carcinoma Southern Florida Society of Medical Oncology
Fort Lauderdale, Florida. April 1993
32.
Novel Uses of InterferonCalifornia. June 1993
+ 5-FU in the
in Oncology St. Vincent’s Hospital Santa Fe, New Mexico. March 1991
Children’s Hospital of San Francisco San Francisco,
in Cancer Santa Barbara Cancer Foundation Santa Barbara, California.
in Solid Tumors Kuakini Medical Center Honolulu, Hawaii. March 1992
Innovations in Cancer Management Conference
Medical Oncology Association of Southern California Newport Beach,
20
33.
Novel Uses of InterferonCalifornia. June 1993
Medical Oncology Association of Southern California La Jolla,
34.
Multimodality Therapy of Rectal Cancer Surgical Grand Round Maine Medical Center Portland,
Maine. October 1993
35.
Biotherapy of Cancer Medical Oncology Board Review Course George Washington University
Medical Center Arlington, Virginia. October 1993
36.
Interleukin-4 in Cancer and Bone Marrow Failure Mt. Sinai Medical Center Chemotherapy
Foundation Symposium New York, New York. November 1993
37.
Biologic Therapy of Renal Cell Carcinoma The New York Hospital-Cornell Medical Center New
York, New York. November 1993
38.
Interferon- in the Treatment of Solid Tumors and Biologic Therapy of Renal Cell Carcinoma
Beth Israel Medical Center New York, New York. November 1993
39.
Interferon- in the Treatment of Solid Tumors Meet the Professor Sessions 7th European
Conference of Clinical Oncology (ECCO7) Jerusalem, Israel. November 1993
40.
Biologic Therapy of Renal Cell Carcinoma Lennox Hill Hospital New York, New York. March
1994
41.
Biologic Therapy of Renal Cell Carcinoma New York University Hospital New York, New York.
March 1994
42.
Biologic Therapy of Colorectal Cancer and Biologic Therapy of Renal Cell Carcinoma Saint Luke’s
Hospital New York, New York. March 1994
43.
Treatment of Malignant Effusions with Intracavitary InterferonNew York, New York. March 1994
44.
Biologic Therapy of Solid Tumors Louisiana State University Medical Center Shreveport, LA. June
1994
45.
Overview of Biological Response Modifiers in Cancer George Washington University Medical
Center Washington, D.C. June 1994
46.
Biologic Therapy of Solid Tumors Washington Hospital Cancer Institute Washington, D.C. June
1994
47.
Biologic Therapy of Renal Cell Carcinoma Ohio State Medical Center Columbus, OH. October
1994
48.
Gastrointestinal Malignancies Chester County Hospital West Chester, PA. October 1994
49.
Phase I Studies With Interleukin-4 Schering-Plough Oncology Interleukin-4 Investigator’s Meeting
Kenilworth, NJ. November 1994
50.
Overview of Interferon-
in Cancer Olive View Medical Center Sylmar, CA. January 1995
51.
Overview of Interferon-
in Cancer West Florida Hospital Pensacola, FL. March 1995
Columbia Presbyterian Hospital
21
52.
Interferon- : Side Effects and Their Management Curriculum Development Roundtable in
Interferons- 1st Annual Update Annenberg Center at Eisenhower Medical Center Rancho Mirage,
California. June 1995
53.
Biologic Therapy of Cancer Charleston Area Medical Center Charleston, WV. August 1995
54.
Biotherapy of Cancer Medical Oncology Board Review Course George Washington University
Medical Center Arlington, Virginia. October 1995
55.
Adjuvant Therapy of Gastric and Colorectal Cancer National Cancer Institute of Italy Workshop on
Stomach and Colorectal Cancers National Institute for the Study and Cure of Cancer Giovanni
Pascale Foundation- Naples, Italy. December 1995
56.
Renal Cell Carcinoma Veterans Administration Hospital Bay Pines, Florida. December 1995
57.
Melanoma Grand Rounds Wilford Hall Medical Center San Antonio, Texas. February 1996
58.
Adjuvant Therapy of High Risk Melanoma Grand Rounds, Terrebonne General Hospital
Houma, Louisiana. March 1996
59.
Melanoma San Antonio Society of Plastic Surgeons San Antonio, Texas. March 1996
60.
Melanoma Brookwood Medical Center Birmingham, Alabama. April 1996
61.
Melanoma Grand Rounds Carraway Methodist Medical Center Birmingham, Alabama. April 1996
62.
Melanoma Internal Medicine Grand Rounds Texas Tech University Health Sciences Center at
Amarillo - Amarillo, Texas. May 1996
63.
Melanoma Medical Oncology Grand Rounds University of Texas, Southwestern School of Medicine
Parkland Memorial Hospital Dallas, Texas. May 1997
64.
Melanoma St. Francis Cabrini Hospital Cancer Center New York, New York. September 1997
65.
Renal Cell Carcinoma Oncology Grand Rounds Medical University of South Carolina
Charleston, South Carolina. October, 1997
66.
Adjuvant Therapy of Melanoma Grand Rounds University of North Texas Health Science Center
Fort Worth, Texas. October, 1997
67.
Adjuvant Therapy of Stage III Melanoma Lymphatic Mapping and Sentinel Lymph Node
Biopsy in Breast Cancer and Melanoma The University of Texas Southwestern Medical Center
Dallas, Texas. October, 1997
68.
Melanoma Fort Worth Surgical Society Fort Worth, Texas. April 1998
69.
Renal Cell Carcinoma Memorial Hospital Tumor Board Colorado Springs, Colorado. April 1999
70.
Biologic Response Modifiers in Renal Cell Carcinoma University of Utah Huntsman Cancer Center
Salt Lake City, Utah. January 2001
22
71.
Adjuvant Therapy of Melanoma with Interferon- Second Annual M. D. Anderson Oncology
Update: Advances and Controversies Steamboat Springs, Colorado. January 2002
72.
Overview of Cytoprotection with Amifostine Grand Rounds University of North Texas Health
Science Center Fort Worth, Texas. July 2003
73.
Update on Renal Cell Carcinoma Cancer 2005: Preferred Treatment and Management Options Hoag
Cancer Center Newport Beach, California. January 2005
74.
Update on Bladder Cancer Cancer 2005: Preferred Treatment and Management Options Hoag
Cancer Center Newport Beach, California. January 2005
75.
Rituxan in Indolent Lymphoma Oncology Grand Rounds The University of Texas Medical Branch
School of Medicine Galveston, Texas. February 2005
76.
Overview of Cytoprotection Luigi’s Restaurant Galveston, Texas. March 2005
77.
Update on Melanoma Essentials in Internal Medicine: Update on Principles and Practice UTMB:
Moody Gardens Hotel Galveston, Texas. April 2005
78.
Moderator for 2005 Rituxan Consultant Initiative Hotel Derek Houston, Texas. April 2005
79.
Moderator for 2005 Rituxan Consultant Initiative Sofitel Water Tower Chicago, Illinois. May 2005
80.
Rituxan (Rituximab) Therapy for the Treatment of Non-Hodgkin’s Lymphoma Wilson, North
Carolina. August 2005
81.
Rituxan (Rituximab) Therapy for the Treatment of Non-Hodgkin’s Lymphoma Austell, Georgia.
August 2005
82.
Rituxan (Rituximab) Therapy for the Treatment of Non-Hodgkin’s Lymphoma Marietta, Georgia.
August 2005
83.
Rituxan (Rituximab) Therapy for the Treatment of Non-Hodgkin’s Lymphoma Cape Girardeau,
Missouri. October 2005
84.
Rituxan (Rituximab) Therapy for the Treatment of Non-Hodgkin’s Lymphoma Sikeston, Missouri.
October 2005
85.
Rituxan (Rituximab) Therapy for the Treatment of Non-Hodgkin’s Lymphoma Herrin, Illinois.
October 2005
86.
Tumor Conference - Coastal Bend Health Education Center B-Cell Non-Hodgkins Malignancies
Corpus Christi, Texas. November 2005
87.
2006 Moderator Workshop for Genentech BioOncology and Rituxan Tucson, Arizona. March 2006
88.
Rituxan (Rituximab) Therapy for the Treatment of Non-Hodgkin’s Lymphoma Omaha, Nebraska.
March 2006
89.
Rituxan (Rituximab) Therapy for the Treatment of Non-Hodgkin’s Lymphoma Council Bluffs,
Iowa. March 2006
23
90.
Rituxan (Rituximab) Therapy for the Treatment of Non-Hodgkin’s Lymphoma Merrillville, Indiana.
March 2006
91.
Rituxan (Rituximab) Therapy for the Treatment of Non-Hodgkin’s Lymphoma Harvey, Illinois.
March 2006
92.
Rituxan (Rituximab) Therapy for the Treatment of Non-Hodgkin’s Lymphoma Oaklawn, Illinois.
March 2006
93.
Rituxan (Rituximab) Therapy for the Treatment of Non-Hodgkin’s Lymphoma Tyler, Texas. March
2006
94.
Rituxan (Rituximab) Therapy for the Treatment of Non-Hodgkin’s Lymphoma Dallas, Texas. April
2006
95.
Rituxan (Rituximab) Therapy for the Treatment of Non-Hodgkin’s Lymphoma Minneapolis,
Minnesota. April 2006
96.
Rituxan (Rituximab) Therapy for the Treatment of Non-Hodgkin’s Lymphoma St. Cloud,
Minnesota. April 2006
97.
Rituxan (Rituximab) Therapy for the Treatment of Non-Hodgkin’s Lymphoma Duluth, Minnesota.
April 2006
98.
Rituxan Advisory Initiative Dallas, Texas. May 2006
99.
Rituxan (Rituximab) Therapy for the Treatment of Relapsed or Refractory, Low-Grade or Follicular,
CD20-Positive, B-Cell Non Hodgkin’s Lymphoma (NHL) Olathe, KS. May 2006
100.
Rituxan (Rituximab) Therapy for the Treatment of Relapsed or Refractory, Low-Grade or Follicular,
CD20-Positive, B-Cell Non Hodgkin’s Lymphoma (NHL) Olathe, KS. May 2006
101.
Rituxan (Rituximab) Therapy for the Treatment of Relapsed or Refractory, Low-Grade or Follicular,
CD20-Positive, B-Cell Non Hodgkin’s Lymphoma (NHL) Olathe, KS. May 2006
102.
Rituxan (Rituximab) Therapy for the First-Line Treatment of Diffuse Large B-Cell, CD20-Positive,
B-Cell Non Hodgkin’s Lymphoma (NHL) in Combination with CHOP or other Anthracycline-Based
Chemotherapy Regimens Pascagoula, MS. May 2006
103.
Rituxan (Rituximab) Therapy for the First-Line Treatment of Diffuse Large B-Cell, CD20-Positive,
B-Cell Non Hodgkin’s Lymphoma (NHL) in Combination with CHOP or other Anthracycline-Based
Chemotherapy Regimens Mobile, AL. May 2006
104.
Rituxan (Rituximab) Therapy for the Front-Line Treatment of Low-Grade or Follicular, CD20Positive, B-Cell Non-Hodgkins Lymphoma Springfield, IL. May 2006
105.
Rituxan (Rituximab) Therapy for the Front-Line Treatment of Low-Grade or Follicular, CD20Positive, B-Cell Non-Hodgkins Lymphoma Alton, IL. May 2006
104.
Rituxan (Rituximab) Therapy for the First-Line Treatment of Diffuse Large B-Cell, CD20-Positive,
B-Cell Non Hodgkin’s Lymphoma (NHL) in Combination with CHOP or other Anthracycline-Based
Chemotherapy Regimens Houston, TX. June 2006
24
105.
Rituxan (Rituximab) Therapy for the First-Line Treatment of Diffuse Large B-Cell, CD20-Positive,
B-Cell Non Hodgkin’s Lymphoma (NHL) in Combination with CHOP or other Anthracycline-Based
Chemotherapy Regimens Columbia, SC. September 2006
106.
Rituxan (Rituximab) Therapy for the First-Line Treatment of Diffuse Large B-Cell, CD20-Positive,
B-Cell Non Hodgkin’s Lymphoma (NHL) in Combination with CHOP or other Anthracycline-Based
Chemotherapy Regimens Charleston, SC. September 2006
109.
Department of Internal Medicine Grand Rounds “TTP” Presented by Dr. Avi Markowitz,
Dr. Jack Alperin, and Dr. Joel David Bessman. June 2007.
110.
Rituxan (Rituximab) Therapy for the Front Line Treatment of Low-grad or Follicular, CD20Positive, B-Cell Non-Hodgkin’s Lymphoma Kingsport, TN. August 2007
111.
Rituxan (Rituximab) Therapy for the Front Line Treatment of Low-grad or Follicular, CD20Positive, B-Cell Non-Hodgkin’s Lymphoma Johnson City, TN. August 2007
112.
Rituxan (Rituximab): FDA approved Indications in CD20-Positive, B-Cell Non-Hodgkin’s
Lymphoma Scottsdale, AZ. October 2007
113.
Update on Non-Hodgkin’s Lymphoma. Texas Academy of Internal Medicine Annual Meeting.
Moody Gardens Hotel Galveston, Texas. November 2007
114.
Malignant Melanoma - Current Treatment Options. Gynecology Oncology Fellowship Didactic
Lecture Series. Galveston, Texas. November 2007
115.
Rituxan (Rituximab) Therapy for the Front Line Treatment of Low-grad or Follicular, CD20Positive, B-Cell Non-Hodgkin’s Lymphoma. Plano, TX. February 2008
25